NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 8, 2025, ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 8, 2025, ...

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 8, 2025 ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 8, 2025, ...

NEW YORK, May 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE: GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 8, 2025, Globus issu ...

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 8, 2025, ...

AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of the Company’s outstanding common stock. “We believe the recent volatility in our share price has created a meaningful disconnect between our intrinsic value and our market valuation,” said Keith Pfeil, Chief Financial Officer and Chief Operating Officer of Globus Medical. “ ...

公司财务表现 - 2025年第一季度非GAAP每股收益为0 68美元 低于市场共识预期0 06美元 [3] - 2025年第一季度营收为5 9812亿美元 低于市场共识预期2778万美元 同比下滑1 4% [3] - 业绩不佳原因包括Enabling Technology交易完成量减少 供应链整合问题 国际分销商订单时间延迟 [3] 股价变动 - 财报发布后股价单日下跌16 64美元 跌幅达22 96% 收盘价报55 82美元 [3] 法律调查 - Pomerantz律师事务所正在调查公司是否存在证券欺诈或其他非法商业行为 [1] - 调查涉及公司及其部分高管和董事 [1] 公司背景 - Globus Medical为纽约证券交易所上市公司 股票代码GMED [1]

For the quarter ended March 2025, Globus Medical (GMED) reported revenue of $598.12 million, down 1.4% over the same period last year. EPS came in at $0.68, compared to $0.72 in the year-ago quarter.The reported revenue represents a surprise of -4.81% over the Zacks Consensus Estimate of $628.32 million. With the consensus EPS estimate being $0.74, the EPS surprise was -8.11%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determin ...

Globus Medical (GMED) came out with quarterly earnings of $0.68 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.11%. A quarter ago, it was expected that this medical device company would post earnings of $0.76 per share when it actually produced earnings of $0.84, delivering a surprise of 10.53%.Over the last four quarters ...